---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product comparison"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Product comparison. Topics: Manufacturer statement of competitive factors and comparator classes; Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels; Elimination half-life, steady state, and metabolism: deucravacitinib, apremilast, and icotrokinra labels; Contraindications and hypersensitivity: deucravacitinib, apremilast, and icotrokinra labels; 16 further topics. 20 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/product-comparison"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Manufacturer statement of competitive factors and comparator classes

> “We believe the key competitive factors that will affect the development and commercial success of our product candidates, if approved, will be efficacy, safety, tolerability profile, convenience of dosing, price and coverage by governmental and third-party payors.”
> “If approved, envu would compete with several currently approved or late-stage oral clinical therapeutics in each such indication as well as other drugs used to treat such patients.”
> “To compete successfully, we need to disrupt these currently marketed drugs, meaning that we will have to demonstrate that the relative cost, method of administration, safety, tolerability and efficacy of our product candidates provide a better alternative to existing and new therapies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.14-2"></a>

### Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels

| Feature | Deucravacitinib label text |
| --- | --- |
| Dosage form and strength | “SOTYKTU (deucravacitinib) tablets are supplied in 6 mg strength for oral administration.” |
| Accumulation with once-daily dosing | “The accumulation of deucravacitinib was <1.4-fold following once daily dosing in healthy subjects.” |
| Tablet handling | “Do not crush, cut, or chew the tablets.” |
| Food | “No clinically significant differences in the pharmacokinetics of deucravacitinib were observed following administration of a high-fat, high-calorie meal” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Feature | Apremilast label text |
| --- | --- |
| Dosage forms and strengths, immediate release | “OTEZLA (apremilast) tablets are supplied in 10 mg, 20 mg, and 30 mg strengths for oral administration.” |
| Dosage form and strength, extended release | “OTEZLA XR (apremilast) extended-release tablets are supplied in a 75 mg strength for oral administration.” |
| Switching between twice-daily and once-daily formulations | “Patients treated with OTEZLA 30 mg twice daily may be switched to OTEZLA XR 75 mg once daily the day following the last dose of OTEZLA 30 mg.” |
| Food | “Administer OTEZLA/OTEZLA XR with or without food.” |
| Tablet handling | “Swallow tablets whole. Do not crush, split, or chew.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Feature | Icotrokinra label text |
| --- | --- |
| Dosage form and strength | “Tablets: 200 mg of icotrokinra, yellowish orange to yellowish brown, oval, film-coated tablets” |
| Tablet handling | “Swallow ICOTYDE whole. Do not crush, split, or chew tablets” |
| Alternative administration | “ICOTYDE 200 mg tablet can also be dispersed in water using the following instructions:” |
| Missed dose | “If a patient misses a dose, instruct patients to take the missed dose as soon as possible with a return to normal dosing schedule the following day.” |
| Food effect | “Icotrokinra AUC decreased by 43% and Cmax decreased by 59% following administration with a high-fat meal (1000 calories, 50% fat)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

### Elimination half-life, steady state, and metabolism: deucravacitinib, apremilast, and icotrokinra labels

| Parameter | Deucravacitinib label text |
| --- | --- |
| Half-life | “The terminal half-life of deucravacitinib was 10 hours.” |
| Active metabolite | “The active deucravacitinib metabolite, BMT-153261, has comparable potency to the parent drug” |
| Metabolic pathways | “Deucravacitinib is also metabolized by CYP2B6, CYP2D6, carboxylesterase (CES) 2, and uridine glucuronyl transferase (UGT) 1A9.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Parameter | Apremilast label text |
| --- | --- |
| Half-life | “The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal elimination half-life of approximately 6-9 hours.” |
| Metabolic pathways | “In vitro, CYP metabolism of apremilast is primarily mediated by CYP3A4, with minor contributions from CYP1A2 and CYP2A6.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Parameter | Icotrokinra label text |
| --- | --- |
| Half-life | “Icotrokinra median elimination half-life is 12 hours with an apparent (oral) clearance of 6550 L/h.” |
| Steady state | “Icotrokinra steady state is reached in approximately 3 days.” |
| Metabolism | “Icotrokinra is a peptide and it is metabolized by peptide catabolism into smaller peptides.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Contraindications and hypersensitivity: deucravacitinib, apremilast, and icotrokinra labels

| Feature | Deucravacitinib label text |
| --- | --- |
| Contraindication | “SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU” |
| Hypersensitivity | “Hypersensitivity reactions, such as angioedema, have been reported in subjects receiving SOTYKTU.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Feature | Apremilast label text |
| --- | --- |
| Contraindication | “OTEZLA/OTEZLA XR is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation” |
| Hypersensitivity | “Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported during post marketing surveillance.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Feature | Icotrokinra label text |
| --- | --- |
| Contraindications | “None.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Infection, hepatitis, and immunization requirements: deucravacitinib and icotrokinra labels

| Requirement | Deucravacitinib label text |
| --- | --- |
| Active infection | “Avoid use of SOTYKTU in patients with an active or serious infection.” |
| Viral hepatitis screening | “Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with SOTYKTU.” |
| Active hepatitis | “SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.” |
| Immunizations before treatment | “Prior to initiating therapy with SOTYKTU, complete all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination.” |
| Live vaccines | “Avoid use of live vaccines in patients treated with SOTYKTU.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Requirement | Icotrokinra label text |
| --- | --- |
| Infection risk | “Medicines that interact with the immune system may increase the risk of infection.” |
| Active infection | “Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated.” |
| Tuberculosis monitoring | “Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment.” |
| Active tuberculosis | “Avoid administering ICOTYDE to patients with active TB.” |
| Immunizations before treatment | “Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.” |
| Vaccine response | “No data are available on the response to live or inactive vaccines.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Pretreatment screening requirements of deucravacitinib and apremilast

> “Before initiating treatment, patients should be screened for tuberculosis (TB) and viral hepatitis, which is not required, for example, before starting apremilast”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

> “Before initiating treatment, screening for tuberculosis, viral hepatitis, and HIV is recommended.”
> “Vaccination status should also be reviewed, and baseline assessment of triglycerides, liver transaminases, and creatine phosphokinase levels should be performed prior to treatment initiation”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

<a id="topic-2.1.2.14-7"></a>

### Laboratory and clinical monitoring: deucravacitinib, apremilast, and icotrokinra labels

| Monitoring item | Deucravacitinib label text |
| --- | --- |
| Liver enzymes | “Evaluate liver enzymes at baseline and during SOTYKTU treatment in patients with known or suspected liver disease.” |
| Creatine phosphokinase | “Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.” |
| Triglyceride change | “Mean triglycerides increased by 10.3 mg/dL during the 16-week treatment period in subjects treated with SOTYKTU and by 9.1 mg/dL during the 52-week treatment period.” |
| Alanine aminotransferase | “ALT elevations ≥3 times the ULN was reported in 9 subjects (3.6 per 100 patient-years) treated with SOTYKTU, and 2 subjects (1.6 per 100 patient-years) treated with placebo.” |
| Malignancy | “Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Monitoring item | Apremilast label text |
| --- | --- |
| Body weight | “Regularly monitor the weight of patients treated with OTEZLA/OTEZLA XR.” |
| Weight decrease of 10% or more | “Weight decrease of ≥ 10% of body weight occurred in 2% (16/784) of subjects treated with OTEZLA 30 mg twice daily compared to 1% (3/382) subjects treated with placebo.” |
| Gastrointestinal events | “There have been reports of severe diarrhea, nausea, and vomiting associated with the use of OTEZLA.” |
| Timing of gastrointestinal events | “Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized.” |
| Older adults | “Because patients 65 years of age or older may be at a higher risk of complications such as volume depletion or hypotension from severe diarrhea, nausea, or vomiting, monitor geriatric patients closely for such complications” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Monitoring item | Icotrokinra label text |
| --- | --- |
| Reduced renal function | “Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min” |
| Anti-drug antibodies | “In four Phase 3 clinical studies through Week 52, 9.6% (199/2083) of subjects treated with ICOTYDE developed anti-drug antibodies.” |
| Neutralizing antibodies | “No neutralizing antibodies were detected.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

> “Adverse reactions that occurred in < 1% of subjects in the ICOTYDE group and at a higher rate than in the placebo group through Week 16 in Trials PSO-1, PSO-2, PSO-3, and PSO-4 were: gastritis, abdominal discomfort, and one fatal case involving upper gastrointestinal bleeding in a subject with underlying risk factors.”
> “A relationship of this event to ICOTYDE is not established.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Drug interactions: deucravacitinib, apremilast, and icotrokinra labels

| Interaction | Deucravacitinib label text |
| --- | --- |
| Effect on coadministered drugs | “No clinically significant differences in the pharmacokinetics of the following drugs were observed when concomitantly administered with deucravacitinib: Rosuvastatin, methotrexate, mycophenolate mofetil (MMF), metformin and oral contraceptives (norethindrone acetate and ethinyl estradiol).” |
| Cytochrome P450 inhibition | “Deucravacitinib is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Interaction | Apremilast label text |
| --- | --- |
| Strong CYP450 inducers | “Co-administration with strong CYP450 inducers (such as rifampin) decreases apremilast exposure and may result in loss of efficacy of OTEZLA/OTEZLA XR” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Interaction | Icotrokinra label text |
| --- | --- |
| Clinical interaction studies | “No formal drug-drug interaction studies have been conducted with icotrokinra. No clinically significant drug interactions have been identified.” |
| Cytochrome P450 enzymes | “Icotrokinra does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### Pregnancy, lactation, pediatric use, and geriatric use: deucravacitinib, apremilast, and icotrokinra labels

| Population | Deucravacitinib label text |
| --- | --- |
| Pregnancy | “Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.” |
| Lactation | “There are no data on the presence of deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production.” |
| Pediatric use | “The safety and effectiveness of SOTYKTU in pediatric patients have not been established.” |
| Geriatric use | “During the Week 0-16 period of the clinical trials 80 subjects ≥ 65 years old, including 12 subjects ≥ 75 years old, who received SOTYKTU without switching treatment arms, had a higher incidence of overall serious adverse reactions, including serious infections, and discontinuations due to adverse reactions compared with younger adult subjects.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Population | Apremilast label text |
| --- | --- |
| Pregnancy, human data | “Available data with OTEZLA use in pregnant women have not identified a drug-associated risk of major birth defects or adverse maternal or fetal outcomes” |
| Pregnancy, animal data | “Based on findings from animal reproduction studies, OTEZLA/OTEZLA XR may increase the risk for fetal loss” |
| Pregnancy counseling | “Advise pregnant women of the potential risk of fetal loss.” |
| Lactation | “There are no data on the presence of apremilast in human milk, its effects on the breastfed infant, or its effects on milk production.” |
| Pediatric use | “The safety and effectiveness of OTEZLA have been established in pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.” |
| Pediatric growth | “Closely monitor growth (height and weight) in pediatric patients treated with OTEZLA.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Population | Icotrokinra label text |
| --- | --- |
| Pregnancy | “The available data on the use of ICOTYDE during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.” |
| Pregnancy safety study | “There is a pregnancy safety study for ICOTYDE.” |
| Lactation | “There are no data on the presence of icotrokinra in human milk, the effects on the breastfed infant, or the effects on milk production.” |
| Pediatric use | “The safety and effectiveness of ICOTYDE in pediatric patients younger than 12 years of age or who weigh less than 40 kg have not been established.” |
| Geriatric use | “No overall differences in safety and effectiveness of ICOTYDE have been observed between subjects 65 years of age and older and younger adult subjects” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Renal and hepatic impairment: deucravacitinib, apremilast, and icotrokinra labels

| Impairment | Deucravacitinib label text |
| --- | --- |
| Renal | “No dose adjustment of SOTYKTU is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis” |
| Hepatic | “SOTYKTU is not recommended for use in patients with severe hepatic impairment (Child-Pugh C)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Impairment | Apremilast label text |
| --- | --- |
| Severe renal, immediate release | “In adult patients with severe renal impairment, reduce the maintenance dosage to OTEZLA 30 mg once daily.” |
| Severe renal, extended release | “OTEZLA XR is not recommended for adult patients with severe renal impairment; the appropriate dosage for these patients has not been determined” |
| Hepatic, population studied | “Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment.” |
| Hepatic, dosage | “No dosage adjustment is necessary in these patients.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Impairment | Icotrokinra label text |
| --- | --- |
| Moderate and severe renal | “Icotrokinra AUC increased by 2.47-fold in patients with moderate (eGFR ≥30 to <60 mL/min, [calculated according to Chronic Kidney Disease Epidemiology Collaboration]) and 2.78-fold in severe (eGFR ≥15 to <30 mL/min) renal impairment.” |
| Hepatic, elimination | “Hepatic impairment is unlikely to affect icotrokinra elimination since the drug is not metabolized hepatically.” |
| Hepatic, severe | “However, patients with severe hepatic impairment were not studied in clinical trials.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Selectivity for TYK2 over JAK1, JAK2, and JAK3 across allosteric TYK2 inhibitors

> “Orthosteric inhibitors with activity against TYK2 (e.g., brepocitinib and ropsacitinib) bind the JAK homology 1 (JH1) domain and compete with the natural substrate, ATP, to occupy the active site”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “In cellular signaling assays, deucravacitinib exhibited more than 100-fold greater selectivity for TYK2 over JAK1 and JAK3, and more than 2000-fold greater selectivity for TYK2 over JAK2”
> “Similarly, zasocitinib showed no measurable inhibition of JAK1/3 or JAK2 signaling in human whole-blood assays”
> “However, biochemical and cellular selectivity should not be equated with superior clinical safety.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1.”

Source: [Mehrotra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40441292/)

> “In contrast, deucravacitinib has an 87-fold greater biochemical selectivity for the TYK2/JH2 domain compared to the JAK1/JH2 domain.”
> “In fact, there is no measurable inhibition of JAK1, JAK2, or JAK3 by envudeucitinib.”
> “Envudeucitinib has a molecular structure that separates it from other TYK2 inhibitors, with a modified arrangement and strategic deuteration sites that contribute to its metabolic stability and pharmacodynamic properties.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Zasocitinib is an allosteric TYK2 inhibitor with a mechanism of action analogous to that of deucravacitinib.”
> “It has been bioengineered to demonstrate enhanced selectivity for the TYK2 JH2 domain.”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

<a id="topic-2.1.2.14-12"></a>

### Duration of TYK2 inhibition across the dosing interval and dosing frequency of TYK2 inhibitors

> “In preclinical and phase 1 studies, oral administration of envudeucitinib twice daily achieved maximal (90% inhibitory concentration [IC90]) TYK2 inhibition over 24 h, highlighting a level of sustained target engagement that distinguishes envudeucitinib from other oral immunomodulators.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “It also exhibits >24 hours of steady state time above IC50 and IC90, indicating prolonged and consistent TYK2 targeting.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition.”

Source: [Mehrotra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40441292/)

> “This suggests that the degree and duration of TYK2i achieved with deucravacitinib 6 mg once daily may limit its efficacy, as also proposed on the basis of pharmacokinetic-pharmacodynamic modeling”
> “Given these differences, pharmacokinetic parameters such as maximum plasma concentration should not be compared directly across agents.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “The study enrolled 606 participants, who received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily up to week 16.”
> “The primary endpoint was the percentage of participants achieving PASI 100 at week 16.”

Source: [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/)

<a id="topic-2.1.2.14-13"></a>

### Efficacy and tolerability of deucravacitinib relative to apremilast and injectable biologics in narrative reviews

> “When compared with apremilast, deucravacitinib exhibits improved tolerability, with fewer discontinuations due to adverse events, as well as greater efficacy, with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) response rates of approximately 55% vs. 37% at week 16”
> “While the efficacy of deucravacitinib is lower than that of most injectable IL-23 or IL-17 inhibitors”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Given its mechanism of action, deucravacitinib causes less modification of cytokine signaling vs other JAK inhibitors, resulting in a narrower adverse effect (AE) profile.”
> “It is the only JAK or TYK2 inhibitor indicated for psoriasis that does not have a boxed warning.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Deucravacitinib was superior to apremilast but inferior to risankizumab”
> “the next-generation agents have been compared only with placebo, apremilast, or deucravacitinib, but not with IL-17 or IL-23 inhibitors.”
> “On current evidence, TYK2i may therefore be regarded as options for patients who prefer or require oral treatment, rather than as alternatives of equivalent efficacy to these biologics.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “Another potential drawback is the need for daily oral dosing, compared with biologic therapies that may allow for injections every 2–3 months”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

<a id="topic-2.1.2.14-14"></a>

### Zasocitinib versus apremilast at week 24 as summarized in a review

> “At week 24, PASI90 responses were 69.0% and 62.7%, compared with 20.4% and 17.0% with apremilast, with no new safety signals”
> “However, the trial has so far been reported only as a congress abstract, and long-term safety data for zasocitinib and envudeucitinib are not yet available.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

<a id="topic-2.1.2.14-15"></a>

### Head-to-head trial: risankizumab versus deucravacitinib in biologic-naive moderate psoriasis, week 16

> “IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy.”
> “In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily.”
> “Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2).”
> “A significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001).”
> “A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A).”
> “In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU.”
> “One potential limitation is that this study employs an open-label design rather than a double-blinded design.”
> “AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.”

Source: [Magnolo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13280295/)

<a id="topic-2.1.2.14-16"></a>

### Matching-adjusted indirect comparison: deucravacitinib versus adalimumab through week 112

> “Before reweighting, on average, patients in the POETYK PSO-LTE (N = 329) versus the REVEAL (N = 345) extension were older, had a lower body weight, received more prior systemic treatments, and had higher baseline PASI scores and week 16 placebo PASI 75 and PASI 90 response rates.”
> “Following reweighting, adjusted week 112 PASI 75 response rates were significantly higher for deucravacitinib versus adalimumab (67.2% vs. 54.0%; mean difference [95% CI], 13.2 [4.0–22.5] percentage points).”
> “Deucravacitinib had a numerically higher adjusted week 112 PASI 90 response rate (41.3% vs. 34.0%; mean difference [95% CI], 7.3 [−2.0 to 16.7] percentage points).”
> “The treatments had similar week 52 adjusted PASI 75 and PASI 90 response rates.”
> “This study was sponsored by Bristol Myers Squibb.”

Source: [Armstrong et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10613163/)

<a id="topic-2.1.2.14-17"></a>

### Network meta-analyses of TYK2 inhibitors and other oral agents

> “In total, 13 RCTs (five for TYK2 inhibitors and eight for PDE4 inhibitors) involving 5274 patients were included.”
> “In addition, deucravacitinib (3 mg BID, 6 mg QD, 6 mg BID, and 12 mg QD), and ropsacitinib (400 mg QD) showed superior efficacy than apremilast (30 mg BID).”
> “In terms of safety, deucravacitinib or ropsacitinib at any dose did not lead to a higher incidence of AEs than apremilast (30 mg BID).”

Source: [Xu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10272578/)

> “Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included.”
> “Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12- 16 weeks.”
> “Tofacitinib (10 mg BID) was considered the most unsafe.”

Source: [Zheng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38899421/)

> “This study included 66 trials of 27,074 patients.”
> “Deucravacitinib has demonstrated moderate efficacy and tolerability; however, additional head-to-head comparative trials are warranted to substantiate its effects due to the paucity of existing studies.”

Source: [Chen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40846809/)

<a id="topic-2.1.2.14-18"></a>

### Manufacturer cross-trial comparison: PASI 100 with envudeucitinib, icotrokinra, and zasocitinib

> “Envudeucitinib: Leading PASI 100 Skin Clearance Across Next Gen Orals, with No Substantial Difference between Envudeucitinib Trials”
> “Note: The results of this retrospective post hoc cross-trial comparison may not be directly comparable.”
> “Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across unrelated studies.”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

| Product | Trial | PASI 100 responders, % |
| --- | --- | --- |
| Envudeucitinib | ONWARD1 | “41.0%” |
| Envudeucitinib | ONWARD2 | “39.5%” |
| Icotrokinra | ICONIC-ADVANCE 1 | “41.5%” |
| Icotrokinra | ICONIC-ADVANCE 2 | “33.2%” |
| Zasocitinib | LATITUDE 3001 | “42.3%” |
| Zasocitinib | LATITUDE 3002 | “32.1%” |

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.1.2.14-19"></a>

### Manufacturer cross-trial comparison: itch improvement of at least 4 points on the PSSD at weeks 2, 4, and 16

> “Envudeucitinib: Earliest and Most Robust ≥4-point Improvement in PSSD Itch Score”
> “PSSD outcomes were assessed using the same validated instrument, endpoint definitions, and assessment timepoints across the programs shown, allowing for a more aligned descriptive comparison.”
> “These are descriptive cross-trial comparisons and should not be interpreted as head-to-head evidence.”
> “Data for icotrokinra and zasocitinib are estimated for weeks 2 and 4 based on line graphs”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

| Trial | Week 2, % | Week 4, % | Week 16, % |
| --- | --- | --- | --- |
| Envudeucitinib, ONWARD1 | “29%” | “44%” | “70%” |
| Envudeucitinib, ONWARD2 | “24%” | “45%” | “64%” |
| Icotrokinra, ICONIC-ADVANCE 1 | “6%” | “22%” | “62%” |
| Icotrokinra, ICONIC-ADVANCE 2 | “6%” | “21%” | “60%” |
| Zasocitinib, LATITUDE 1 | “4%” | “23%” | “51%” |
| Zasocitinib, LATITUDE 2 | “5%” | “24%” | “58%” |

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.1.2.14-20"></a>

### Absence of head-to-head trials and formal indirect comparisons that include envudeucitinib

> “Additionally, direct (e.g., head-to-head) and formal indirect (e.g., meta-analyses) comparisons of oral agents for the treatment of psoriasis are not presently available.”
> “By achieving full target engagement without compromising safety, envudeucitinib may offer efficacy comparable to biologics (e.g., IL-23 and IL-17 inhibitors) in an oral formulation.”
> “Medical writing assistance was funded by Alumis Inc. The journal’s Rapid Service Fee was funded by Alumis Inc.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Moreover, comparisons between agents are largely indirect and limited by differences in study populations, endpoints, and timing, and the pharmacokinetic data summarized in Table 1 derive from heterogeneous doses and populations.”
> “First, it remains uncertain whether next-generation inhibitors differ meaningfully from deucravacitinib.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “In addition, comparisons between studies are limited as varying methodologies were used.”
> “As more TYK2 inhibitors, such as zasocitinib and envudeucitinib, emerge, additional studies will be essential to delineate differences in efficacy, safety, and long-term outcomes.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Solid comparative data are currently available for apremilast; however, a key limitation is the lack of head-to-head studies with newer biologics, such as IL-17 and IL-23 inhibitors.”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
